Stock Track | Arrowhead Pharmaceuticals Soars 5.01% on FDA Breakthrough Therapy Designation for Plozasiran

Stock Track12-03

Arrowhead Pharmaceuticals (ARWR) saw its stock surge 5.01% intraday on Tuesday, driven by positive regulatory and analyst developments.

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to Arrowhead's experimental drug, Plozasiran, for the treatment of severe hypertriglyceridemia. This designation accelerates the development and review process for drugs that show significant promise in addressing serious conditions. Arrowhead plans to complete Phase 3 studies by mid-2026 and submit a supplemental new drug application by the end of 2026.

Additionally, HC Wainwright & Co. maintained its "Buy" rating on the stock and raised the target price to $85 from $80, further bolstering investor confidence.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1175986823?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-03 01:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175986823","market":"us","top_or_hot":-1,"title":"Stock Track | Arrowhead Pharmaceuticals Soars 5.01% on FDA Breakthrough Therapy Designation for Plozasiran","media":"Stock Track","content":"<p>Arrowhead Pharmaceuticals (ARWR) saw its stock surge 5.01% intraday on Tuesday, driven by positive regulatory and analyst developments.</p><p>The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to Arrowhead's experimental drug, Plozasiran, for the treatment of severe hypertriglyceridemia. This designation accelerates the development and review process for drugs that show significant promise in addressing serious conditions. Arrowhead plans to complete Phase 3 studies by mid-2026 and submit a supplemental new drug application by the end of 2026.</p><p>Additionally, HC Wainwright & Co. maintained its \"Buy\" rating on the stock and raised the target price to $85 from $80, further bolstering investor confidence.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Arrowhead Pharmaceuticals Soars 5.01% on FDA Breakthrough Therapy Designation for Plozasiran</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Arrowhead Pharmaceuticals Soars 5.01% on FDA Breakthrough Therapy Designation for Plozasiran\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-12-03 01:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Arrowhead Pharmaceuticals (ARWR) saw its stock surge 5.01% intraday on Tuesday, driven by positive regulatory and analyst developments.</p><p>The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to Arrowhead's experimental drug, Plozasiran, for the treatment of severe hypertriglyceridemia. This designation accelerates the development and review process for drugs that show significant promise in addressing serious conditions. Arrowhead plans to complete Phase 3 studies by mid-2026 and submit a supplemental new drug application by the end of 2026.</p><p>Additionally, HC Wainwright & Co. maintained its \"Buy\" rating on the stock and raised the target price to $85 from $80, further bolstering investor confidence.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARWR","symbol_name":"Arrowhead Research Corporation","start_time":0,"source_url":"","article_id":"1175986823","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175986823","pubTimestamp":1764696025,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Arrowhead Pharmaceuticals (ARWR) saw its stock surge 5.01% intraday on Tuesday, driven by positive regulatory and analyst developments.The U.S. Food and Drug Administration (FDA) granted Breakthrough...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARWR":"Arrowhead Research Corporation"},"translate_title":"个股追踪|Arrowhead Pharmaceuticals因Plozasiran获FDA突破性疗法认定飙升5.01%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARWR":1},"content_text":"Arrowhead Pharmaceuticals (ARWR) saw its stock surge 5.01% intraday on Tuesday, driven by positive regulatory and analyst developments.The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to Arrowhead's experimental drug, Plozasiran, for the treatment of severe hypertriglyceridemia. This designation accelerates the development and review process for drugs that show significant promise in addressing serious conditions. Arrowhead plans to complete Phase 3 studies by mid-2026 and submit a supplemental new drug application by the end of 2026.Additionally, HC Wainwright & Co. maintained its \"Buy\" rating on the stock and raised the target price to $85 from $80, further bolstering investor confidence.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1175986823","isCrawlerRequest":true}